



Claims

1. An ecdysteroid derivative wherein a fluorescent moiety is attached to an ecdysteroid moiety by derivatisation of a hydroxyl group on the alkyl side chain of the ecdysteroid moiety, wherein the derivative is capable of binding to an ecdysone receptor or ligand binding domain thereof.
2. An ecdysteroid derivative according to claim 1 wherein the derivative has general structure 1a, 2a, or 3a;



10



- wherein B is CH₂O, CH₂S, CH₂NH, O, S, or NH; X is a linking group; A is a fluorescent moiety; R¹-R⁵ are independently selected from H, alkyl, haloalkyl, OH, or halogen, R⁷-R⁸ are independently selected from H, alkyl, haloalkyl, OH, or halogen or R⁷ and R⁸ together are =CH₂; R⁶ is selected from H, OH, alkyl, =CH₂ or halogen, or R⁶ together with R⁷ is a double bond.

3. A derivative according to claim 2 wherein the alkyl groups are C1 to C20, more preferably, for R¹ and R² the alkyl group is C1 to C5.
4. A derivative according to claim 2 wherein R¹, and R⁵ are OH; R² is H or OH; R³ is H; R⁴ is H or OH; R⁶ is selected from H, OH, CH₃, CH₃CH₂, or (CH₃)₂CH; R⁷ and R⁸ are






20

BEST AVAILABLE COPY




independently selected from H, OH, CH₃, or R⁷ and R⁸ together can be = CH₂, R⁶ together with R⁷ can be a double bond.

5. A derivative according to any one of claims 2 to 4 wherein X is selected from the group consisting of C(O)NH, C(S)NH, SO₂ and C(O).
- 5 6. A derivative according to any one of claims 2 to 5 wherein B is CH₂O or O.
7. A derivative according to any one of claims 2 to 6 wherein the fluorescent moiety is selected from the group consisting of unsubstituted and substituted fluorescein moieties, unsubstituted and substituted dansyl moieties, and unsubstituted and substituted coumarin moieties.
- 10 8. A derivative according to any one of claims 2 to 7 wherein the derivative is of general structure 1a wherein R¹ and R⁵ are OH, R³ is H, R⁷ is CH₃, and B is CH₂O and X is selected from the group consisting of C(O)NH, C(S)NH, SO₂ and C(O).
9. A derivative according to claim 8 wherein R², R⁴, and R⁸ are independently selected from H, alkyl, OH, or halogen; R⁶ is selected from H, OH, alkyl, =CH₂ or halogen.
- 15 10. A derivative according to claim 9 wherein R² is H, R⁴ is OH, R⁶ is H and R⁸ is H.
11. A derivative according to any one of claims 2 to 7 wherein R¹, R⁴ and R⁵ are OH, R² is H or OH, R³ is H, R⁶ is H or CH₃, and R⁷ and R⁸ are H or CH₃.
12. A derivative according to any one of claims 1 to 11 wherein the ccdysteroid moiety is selected from the group consisting of inokosterone, 26-hydroxyecdysone, 20,26-
20 dihydroxyecdysone, makisterone B, amarasterone A, amarasterone B, ajugasterone B, sidasterone A, sidasterone B, 26-hydroxy-polypodine B, 20-hydroxyecdysone, makisterone A, polypodine B and rapisterone D.

13. A derivative according to any one of claims 1 to 12 wherein the derivative is selected from the group consisting of:

**MB4628****MB4592****MB4603****MB4622**

14. An ecdysteroid derivative according to claim 1 wherein the derivative has general structure 1b, 2b, or 3b;




wherein B is CH_2O , CH_2S , CH_2NH , O , S , or NH ; X is a linking group; A is a fluorescent moiety; $\text{R}^1\text{-R}^4$, $\text{R}^7\text{-R}^9$ are independently selected from H, alkyl, haloalkyl, OFI, or halogen; R^6 is selected from H, OH, alkyl, $=\text{CH}_2$ or halogen.

15. A derivative according to claim 14 wherein the alkyl groups are C1 to C20, more preferably, for R^1 and R^2 the alkyl group is C1 to C5.

16. A derivative according to any one of claims 14 to 15 wherein X is selected from the group consisting of $\text{C}(\text{O})\text{NH}$, $\text{C}(\text{S})\text{NH}$, SO_2 , and $\text{C}(\text{O})$.

17. A derivative according to any one of claims 14 to 16 wherein the fluorescent moiety is selected from the group consisting of unsubstituted and substituted fluorescein moieties, unsubstituted and substituted dansyl moieties, and unsubstituted and substituted coumarin moieties.






18. A derivative according to any one of claims 14 to 17 wherein R^1 and R^4 are OH; R^2 and R^3 are independently selected from H or OH; R^6 is selected from H or CH_3 , and R^7 , R^8 and R^9 are independently selected from the group H, OH, CH_3 , F, and I.
19. A derivative according to any one of claims 14 to 18 wherein the ecdysteroid moiety is selected from the group consisting of ponasterone A, 20-hydroxyecdysone, muristerone A, makisterone A, polypodine B, rapisterone D, $2\beta,3\beta,20R,22R$ -tetrahydroxy-25-fluoro- 5β -cholest-8,14-dien-6-one, 5-deoxykaladasterone, 26-iodoponasterone A, and 25-fluoroponasterone A.
20. A compound selected from the group of compounds consisting of general structures 1a, 2a, and 3a which interact with an ecdysone receptor or ligand binding domain (LBD) thereof;






15

- wherein B is CH_2O , CH_2S , CH_2NH , O, S, or NH; X is a linking group; A is a fluorescent moiety; R^1 - R^5 are independently selected from H, alkyl, haloalkyl, OH, or halogen, R^7 - R^8 are independently selected from H, alkyl, haloalkyl, OH, or halogen or R^7 and R^8 together are $=CH_2$; R^6 is selected from H, OH, alkyl, $=CH_2$ or halogen, or R^6 together with R^7 is a double bond.
- 20

21. A compound according to claim 20 wherein the alkyl groups are C1 to C20, more preferably, for R^1 and R^2 the alkyl group is C1 to C5.
22. A compound according to claim 20 or 21 wherein R^1 , and R^5 are OH; R^2 is H or OH; R^3 is H; R^4 is H or OH; R^6 is selected from H, OH, CH_3 , CH_3CH_2 or $(CH_3)_2CH$; R^7 and R^8 are independently selected from H, OH, CH_3 , or R^7 and R^8 together can be $=CH_2$, R^6 together with R^7 can be a double bond.
23. A compound according to any one of claims 20 to 22 wherein X is selected from the group consisting of $C(O)NH$, $C(S)NH$, SO_2 and $C(O)$.
24. A compound according to any one of claims 20 to 23 wherein B is CF_2O or O.
- 10 25. A compound according to any one of claims 20 to 24 wherein the fluorescent moiety is selected from the group consisting of unsubstituted and substituted fluorescein moieties, unsubstituted and substituted dansyl moieties, and unsubstituted and substituted coumarin moieties..
- 15 26. A compound according to any one of claims 20 to 25 wherein the compound is of general structure 1a wherein R^1 and R^5 are OH, R^3 is H, R^7 is CH_3 , and B is CH_2O and X is selected from the group consisting of $C(O)NH$, $C(S)NH$, SO_2 and $C(O)$.
27. A compound according to claim 26 wherein R^2 , R^4 , and R^8 are independently selected from H, alkyl, OH, or halogen; R^6 is selected from H, OH, alkyl, $=CH_2$ or halogen.
28. A compound according to claim 27 wherein R^2 is H, R^4 is OH, R^6 is H and R^8 is H.
- 20 29. A compound according to any one of claims 20 to 28 wherein R^1 , R^4 and R^5 are OH, R^2 is H or OH, R^3 is H, R^6 is H or CH_3 , and R^7 and R^8 are CF_3 .
- 25 30. A compound according to any one of claims 20 to 29 wherein the fluorescent moiety is attached by derivatisation to an ecdysteroid selected from the group consisting of inokosterone, 26-hydroxyecdysone, 20,26-dihydroxyecdysone, makisterone B, amarasterone A, amarasterone B, ajugasterone B, sidasterone A, sidasterone B, 26-hydroxy-polypodine B, 20-hydroxyecdysone, makisterone A, polypodine B and rapisterone D.
31. A compound according to any one of claims 20 to 30 wherein the compound is selected from the group consisting of:



32. A compound selected from the group of compounds consisting of general structures 1b, 2b, and 3b which interact with an ecdysone receptor or ligand binding domain (LBD) thereof;



wherein B is CH₂O, CH₂S, CH₂NH, O, S, or NH; X is a linking group; A is a fluorescent moiety; R¹-R⁴, R⁷-R⁹ are independently selected from H, alkyl, haloalkyl, OH, or halogen; R⁶ is selected from H, OH, alkyl, =CH₂ or halogen.

33. A compound according to claim 32 wherein the alkyl groups are C1 to C20, more preferably, for R¹ and R² the alkyl group is C1 to C5.
34. A compound according to any one of claims 32 to 33 wherein X is selected from the group consisting of C(O)NH, C(S)NH, SO₂, and C(O).
35. A compound according to any one of claims 32 to 34 wherein the fluorescent moiety is selected from the group consisting of unsubstituted and substituted fluorescein moieties, unsubstituted and substituted dansyl moieties, and unsubstituted and substituted coumarin moieties.
36. A compound according to any one of claims 32 to 35 wherein R¹ and R⁴ are OH; R² and R³ are independently selected from H or OH; R⁶ is selected from H or CH₃, and R⁷, R⁸ and R⁹ are independently selected from the group H, OH, CH₃, F, and I.

37. A compound according to any one of claims 32 to 36 wherein the fluorescent moiety is attached by derivatisation to an ecdysteroid is selected from the group consisting of ponasterone A, 20-hydroxyecdysone, muristerone A, makisterone A, polypodine B, rapisterone D, 2 β ,3 β ,20*R*,22*R*-tetrahydroxy-25-fluoro-5 β -cholest-8,14-dien-6-one, 5-
5 deoxykaladasterone, 26-iodoponasterone A, and 25-fluoroponasterone A.

38. A compound which is an ecdysteroid mimic wherein the compound comprises a non-ecdysteroid moiety that interacts with an ecdysone receptor or ligand binding domain thereof, and wherein the compound further comprises a fluorescent moiety.

39. A compound according to claim 38 wherein the compound comprises a substituted or
10 unsubstituted dibenzoyl hydrazine moiety that interacts with an ecdysone receptor or ligand binding domain thereof, and wherein the compound further comprises a fluorescent moiety attached through a phenyl ring substituent or a nitrogen atom in the dibenzoyl hydrazine moiety.

40. A method for screening a candidate compound for its ability to interact with an
15 ecdysone receptor or ligand binding domain (LBD) thereof in a competitive inhibition format, the method comprising the steps of:

(a) incubating with an ecdysone receptor or LBD thereof, a candidate compound and the derivative according to any one of claims 1 to 19; and

(b) measuring the extent of binding of the derivative according to any one of claims
20 1 to 19 to the ecdysone receptor or LBD thereof.

41. A method for screening a candidate compound for its ability to interact with an ecdysone receptor or ligand binding domain (LBD) thereof in a competitive inhibition format, the method comprising the steps of:

(a) incubating with an ecdysone receptor or LBD thereof, a candidate compound
25 and the compound according to any one of claims 20 to 37; and

(b) measuring the extent of binding of the compound according to any one of claims
20 to 37 to the ecdysone receptor or LBD thereof.

42. A method for screening a candidate compound for its ability to interact with an ecdysone receptor or ligand binding domain (LBD) thereof in a competitive inhibition
30 format, the method comprising the steps of:

(a) incubating with an ecdysone receptor or LBD thereof, a candidate compound and the derivative according to any one of claims 38 or 39; and

(b) measuring the extent of binding of the derivative according to any one of claims 38 or 39 to the ecdysone receptor or LBD thereof.

- 5 43. A method according to any one of claims 40-42 wherein the competitive inhibition format is a fluorescence polarization assay.
44. A method according to any one of claims 40 to 43, wherein the assay is conducted in a microtitre plate well.
45. An insecticidal compound identified by the assay according to any one of claims 40
10 to 44.
46. An effector compound for ecdysone receptor gene switches, the compound identified by the assay according to any one of claims 40 to 44.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.